Vertex's experimental pain drug fails main goal in mid-stage study-February 2024-www.financetom.com

Vertex's experimental pain drug fails main goal in mid-stage study

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Vertex's experimental pain drug fails main goal in mid-stage study

Aug 4, 2025 1:19 PM

Aug 4 (Reuters) - Vertex Pharmaceuticals ( VRTX ) said

on Monday its next generation oral drug failed to meet the main

goal of a keenly-watched mid-stage trial.

Previous page： Insight Acquisition Receives Nasdaq Non-Compliance Notice Next page： J&J to buy medical device maker V-Wave for up to $1.7 bln

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Insight Acquisition Receives Nasdaq Non-Compliance Notice

Aug 20, 2024

11:42 AM EDT, 08/20/2024 (MT Newswires) -- Insight Acquisition ( INAQ ) said Tuesday that it received a Nasdaq notice dated July 29 that its listed securities failed to comply with the $15 million market value requirement for continue listing. Nasdaq granted Insight a 180-day period, until Jan. 27, 2025, to regain compliance, which would require its securities to close...

J&J to buy medical device maker V-Wave for up to $1.7 bln

Aug 20, 2024

Aug 20 (Reuters) - Johnson & Johnson ( JNJ ) said on Tuesday it would buy privately held V-Wave for up to $1.7 billion, the healthcare conglomerate's second deal this year aimed at boosting its presence in the market for heart disease devices. J&J said it will pay $600 million upfront, with potential payments of up to $1.1 billion contingent...